These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 20549300)
1. Expression of vascular endothelial growth factor and matrix metalloproteinase-9 in sacral chordoma. Chen KW; Yang HL; Lu J; Wang GL; Ji YM; Wu GZ; Zhu LF; Liu JY; Chen XQ; Gu YP J Neurooncol; 2011 Feb; 101(3):357-63. PubMed ID: 20549300 [TBL] [Abstract][Full Text] [Related]
2. High expression of survivin in sacral chordoma. Chen C; Yang HL; Chen KW; Wang GL; Lu J; Yuan Q; Gu YP; Luo ZP Med Oncol; 2013 Jun; 30(2):529. PubMed ID: 23504337 [TBL] [Abstract][Full Text] [Related]
3. Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis. Chen K; Mo J; Zhou M; Wang G; Wu G; Chen H; Zhang K; Yang H Med Oncol; 2014 Apr; 31(4):886. PubMed ID: 24535608 [TBL] [Abstract][Full Text] [Related]
4. Analysis of risk factors for recurrence after the resection of sacral chordoma combined with embolization. Yang H; Zhu L; Ebraheim NA; Liu X; Castillo S; Tang T; Liu J; Cui H Spine J; 2009 Dec; 9(12):972-80. PubMed ID: 19800296 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of Raf-1 and ERK1/2 in sacral chordoma and association with tumor recurrence. Zhang K; Chen H; Zhang B; Sun J; Lu J; Chen K; Yang H Int J Clin Exp Pathol; 2015; 8(1):608-14. PubMed ID: 25755752 [TBL] [Abstract][Full Text] [Related]
6. High expression of SPHK1 in sacral chordoma and association with patients' poor prognosis. Zhang K; Chen H; Wu G; Chen K; Yang H Med Oncol; 2014 Nov; 31(11):247. PubMed ID: 25260803 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of CD40 in sacral chordomas and its correlation with low tumor recurrence. Li X; Wang S; Chen Y; Liu G; Yang X Onkologie; 2013; 36(10):567-71. PubMed ID: 24107910 [TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of VEGF receptors expression on the tumor cells in skull base chordoma. Morimoto Y; Tamura R; Ohara K; Kosugi K; Oishi Y; Kuranari Y; Yoshida K; Toda M J Neurooncol; 2019 Aug; 144(1):65-77. PubMed ID: 31240525 [TBL] [Abstract][Full Text] [Related]
9. C-reactive protein as a prognostic factor in patients with chordoma of lumbar spine and sacrum--a single center pilot study. Hobusch GM; Bodner F; Walzer S; Marculescu R; Funovics PT; Sulzbacher I; Windhager R; Panotopoulos J World J Surg Oncol; 2016 Apr; 14():111. PubMed ID: 27091202 [TBL] [Abstract][Full Text] [Related]
10. Correlation of vascular endothelial growth factor expression with tumor recurrence and poor prognosis in patients with pN0 gastric cancer. Liu YF; Guo S; Zhao R; Chen YG; Wang XQ; Xu KS World J Surg; 2012 Jan; 36(1):109-17. PubMed ID: 21773953 [TBL] [Abstract][Full Text] [Related]
11. ADAM10 Is a Potential Novel Prognostic Biomarker for Sacral Chordoma. Ding Y; Bui MM; Wang Q; Sun X; Zhang M; Niu X; Tian W Ann Clin Lab Sci; 2019 May; 49(3):309-316. PubMed ID: 31308029 [TBL] [Abstract][Full Text] [Related]
12. Expression of insulin-like growth factor II mRNA-binding protein 3 (IMP3) in sacral chordoma. Zhou M; Chen K; Yang H; Wang G; Lu J; Ji Y; Wu C; Chen C J Neurooncol; 2014 Jan; 116(1):77-82. PubMed ID: 24135846 [TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma. Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H Eur Spine J; 2014 Nov; 23(11):2416-22. PubMed ID: 24929808 [TBL] [Abstract][Full Text] [Related]
14. Expression of matrix metalloproteinase-9 mRNA and vascular endothelial growth factor protein in gastric carcinoma and its relationship to its pathological features and prognosis. Yang Q; Ye ZY; Zhang JX; Tao HQ; Li SG; Zhao ZS Anat Rec (Hoboken); 2010 Dec; 293(12):2012-9. PubMed ID: 21089052 [TBL] [Abstract][Full Text] [Related]
15. Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis. Froehlich EV; Scheipl S; Lazàry A; Varga PP; Schmid C; Stammberger H; Beham A; Bodo K; Schroettner H; Quehenberger F; Windhager R; Liegl B; Leithner A Spine (Phila Pa 1976); 2012 Jun; 37(13):E757-67. PubMed ID: 22228328 [TBL] [Abstract][Full Text] [Related]
16. Surgical treatment of sacral chordomas combined with transcatheter arterial embolization. Yang H; Zhu L; Ebraheim NA; Liu J; Shapiro A; Castillo S; Liu X; Tang T J Spinal Disord Tech; 2010 Feb; 23(1):47-52. PubMed ID: 20084025 [TBL] [Abstract][Full Text] [Related]
17. Sacral chordoma: a clinical review of 101 cases with 30-year experience in a single institution. van Wulfften Palthe ODR; Tromp I; Ferreira A; Fiore A; Bramer JAM; van Dijk NC; DeLaney TF; Schwab JH; Hornicek FJ Spine J; 2019 May; 19(5):869-879. PubMed ID: 30445184 [TBL] [Abstract][Full Text] [Related]
18. Expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and matrix metalloproteinase-2 in sacral chordomas. Li X; Ji Z; Ma Y; Qiu X; Fan Q; Ma B Oncol Lett; 2012 Jun; 3(6):1268-1274. PubMed ID: 22783431 [TBL] [Abstract][Full Text] [Related]
19. Expression of IMP3 and IGF2 in giant cell tumor of spine is associated with tumor recurrence and angiogenesis. Zhang K; Zhou M; Chen H; Wu G; Chen K; Yang H Clin Transl Oncol; 2015 Jul; 17(7):570-5. PubMed ID: 25740666 [TBL] [Abstract][Full Text] [Related]
20. What Are the Conditional Survival and Functional Outcomes After Surgical Treatment of 115 Patients With Sacral Chordoma? Ji T; Guo W; Yang R; Tang X; Wang Y; Huang L Clin Orthop Relat Res; 2017 Mar; 475(3):620-630. PubMed ID: 26975382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]